Prognosis of children and young adults with newly diagnosed rhabdomyosarcoma metastatic to bone marrow treated on Children's Oncology Group studies

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. Metastatic disease occurs in 16% of all RMS cases and has a poor prognosis. There are limited studies examining the outcomes specific to patients with RMS metastatic to bone marrow despite an incidence of 6% at diagnosis. Our study aims to document the outcomes, prognostic factors, and clinical courses of children presenting with RMS metastatic to bone marrow treated on Children's Oncology Group (COG) cooperative trials.

[1]  A. Ferrari,et al.  Metastatic rhabdomyosarcoma: Evidence of the impact of radiotherapy on survival. A retrospective single‐center experience , 2022, Pediatric blood & cancer.

[2]  D. Hawkins,et al.  Is Detection of Relapse by Surveillance Imaging Associated With Longer Survival in Patients With Rhabdomyosarcoma? , 2022, Journal of pediatric hematology/oncology.

[3]  L. Wexler,et al.  Pediatric rhabdomyosarcoma with bone marrow metastasis , 2020, Pediatric blood & cancer.

[4]  J. H. van der Lee,et al.  Is surveillance imaging in pediatric patients treated for localized rhabdomyosarcoma useful? The European experience , 2019, Cancer.

[5]  D. Rodeberg,et al.  Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group , 2019, Cancer medicine.

[6]  James R. Anderson,et al.  The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma , 2018, Cancer.

[7]  Kyung-Ja Cho,et al.  Clinical and Cytogenetic Profiles of Rhabdomyosarcoma with Bone Marrow Involvement in Korean Children: A 15-Year Single-Institution Experience , 2017, Annals of laboratory medicine.

[8]  James R. Anderson,et al.  Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group , 2017, Pediatric blood & cancer.

[9]  James R. Anderson,et al.  Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  James R. Anderson,et al.  Histologic and clinical characteristics can guide staging evaluations for children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  L. Mariani,et al.  Comparison of the prognostic value of assessing tumor diameter versus tumor volume at diagnosis or in response to initial chemotherapy in rhabdomyosarcoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  James R. Anderson,et al.  Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  F. Ullrich,et al.  Results in patients with cranial parameningeal sarcoma and metastases (Stage 4) treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols II–IV, 1978–1997: Report from the Children's Oncology Group , 2008, Pediatric blood & cancer.

[14]  James R. Anderson,et al.  Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  James R. Anderson,et al.  Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Carli,et al.  European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  P. Sorensen,et al.  PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  James R. Anderson,et al.  Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  P. Sorensen,et al.  Ifosfamide and Etoposide Are Superior to Vincristine and Melphalan for Pediatric Metastatic Rhabdomyosarcoma When Administered With Irradiation and Combination Chemotherapy: A Report From the Intergroup Rhabdomyosarcoma Study Group , 2001, Journal of pediatric hematology/oncology.

[20]  M. Carli,et al.  High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Sorensen,et al.  Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Carli,et al.  Response of previously untreated metastatic rhabdomyosarcoma to combination chemotherapy with carboplatin, epirubicin and vincristine. , 1996, European journal of cancer.

[23]  E. Gehan,et al.  The intergroup rhabdomyosarcoma study‐II , 1993, Cancer.

[24]  E. Gehan,et al.  Disease patterns and survival rate in children with metastatic soft‐tissue sarcoma: A report from the intergroup rhabdomyosarcoma study (IRS)‐I , 1988, Cancer.

[25]  E. Gehan,et al.  The intergroup rhabdomyosarcoma study‐I. A final report , 1988, Cancer.

[26]  R. Arceci.  Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group , 2008 .

[27]  James R. Anderson,et al.  Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  C. R. Pinkerton,et al.  Metastatic rhabdomyosarcoma and histologically similar tumors in childhood: a retrospective European multi-center analysis. , 1992, Medical and pediatric oncology.